About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
 
  CLS Portfolio Companies
  Amaranth Medical, Inc.
  APT Pharmaceuticals, Inc.
  Comentis, Inc.
  CoRepair, Inc.
  EnteroMedics, Inc.
  Great Lakes Pharmaceuticals, Inc.
  Health Fidelity, Inc.
  Inviragen, Inc.
  Kereos, Inc.
  KFx Medical Corporation
  Minimally Invasive Devices, Inc.
  Mirabilis Medica, Inc.
  Revascular Therapeutics, Inc.
  XLumena
  Visioneering Technologies, Inc.
   
   

 

 
     
 

CLS Portfolio Companies

       
     
     
 
 
Amaranth Medical Inc. is developing a new generation of bioresorbable stents.
     
     
 
 
APT Pharmaceuticals, Inc. is developing pulmonary delivered drugs for respiratory diseases.
   
 
 
 
 
CoMentis, Inc.is developing small molecule drugs for treating age-related macular degeneration (AMD), Alzheimer’s Disease and other cognitive disorders.
   
 
 
     
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
   
 
 
 
 
EnteroMedics, Inc. is developing a medical device that treats obesity through modulation of vagus nerve activity.
   
 
 
 
 
Great Lakes Pharmaceuticals, Inc.has developed an anti-microbial, anti-coagulant catheter lock solution for the prevention and treatment of catheter related blood stream infections (CRBSI).
   
 
 
 
 
Health Fidelity, Inc. is developing and marketing a clinical natural language processing platform that automates the extraction of data from unstructured clinical text collected within healthcare organizations.
   
 
 
 
 
Inviragen, Inc. is developing vaccines for the global market.
   
 
 
 
 
Kereos, Inc. is developing imaging agents and therapeutic drugs for oncology and cardiovascular disease.
   
 
 
 
 
KFx Medical Corporation is developing a device system for repair of rotator cuff injuries.
 
 
 
 
 
Minimally Invasive Devices, Inc. is developing a tools to facilitate laparoscopic surgery.
 
 
 
 
 
Mirabilis Medica, Inc. is developing a HIFU-based system for the ablation of uterine fibroids.
 
     
 
 
Revascular Therapeutics, Inc. is developing a device system for treatment of total occlusions in the peripheral and coronary arteries.
 
     
 
 
XLumena, Inc. is an endosurgery company developing novel medical devices that enable translumenal EUS therapy.
     
       
 
 
Visioneering Technologies, Inc. has developed next generation optics technology for ophthalmic devices that can simultaneously correct near and distance vision.
 
 
   
 
 
© 2006 CHARTER LIFE SCIENCES